Cargando…

Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus

There is a close relationship between diabetes mellitus and heart failure, and diabetes is an independent risk factor for heart failure. Diabetes and heart failure are linked by not only the complication of ischemic heart disease, but also by metabolic disorders such as glucose toxicity and lipotoxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Kazufumi, Miyoshi, Toru, Yoshida, Masashi, Akagi, Satoshi, Saito, Yukihiro, Ejiri, Kentaro, Matsuo, Naoaki, Ichikawa, Keishi, Iwasaki, Keiichiro, Naito, Takanori, Namba, Yusuke, Yoshida, Masatoki, Sugiyama, Hiroki, Ito, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999085/
https://www.ncbi.nlm.nih.gov/pubmed/35408946
http://dx.doi.org/10.3390/ijms23073587
_version_ 1784685106291539968
author Nakamura, Kazufumi
Miyoshi, Toru
Yoshida, Masashi
Akagi, Satoshi
Saito, Yukihiro
Ejiri, Kentaro
Matsuo, Naoaki
Ichikawa, Keishi
Iwasaki, Keiichiro
Naito, Takanori
Namba, Yusuke
Yoshida, Masatoki
Sugiyama, Hiroki
Ito, Hiroshi
author_facet Nakamura, Kazufumi
Miyoshi, Toru
Yoshida, Masashi
Akagi, Satoshi
Saito, Yukihiro
Ejiri, Kentaro
Matsuo, Naoaki
Ichikawa, Keishi
Iwasaki, Keiichiro
Naito, Takanori
Namba, Yusuke
Yoshida, Masatoki
Sugiyama, Hiroki
Ito, Hiroshi
author_sort Nakamura, Kazufumi
collection PubMed
description There is a close relationship between diabetes mellitus and heart failure, and diabetes is an independent risk factor for heart failure. Diabetes and heart failure are linked by not only the complication of ischemic heart disease, but also by metabolic disorders such as glucose toxicity and lipotoxicity based on insulin resistance. Cardiac dysfunction in the absence of coronary artery disease, hypertension, and valvular disease is called diabetic cardiomyopathy. Diabetes-induced hyperglycemia and hyperinsulinemia lead to capillary damage, myocardial fibrosis, and myocardial hypertrophy with mitochondrial dysfunction. Lipotoxicity with extensive fat deposits or lipid droplets is observed on cardiomyocytes. Furthermore, increased oxidative stress and inflammation cause cardiac fibrosis and hypertrophy. Treatment with a sodium glucose cotransporter 2 (SGLT2) inhibitor is currently one of the most effective treatments for heart failure associated with diabetes. However, an effective treatment for lipotoxicity of the myocardium has not yet been established, and the establishment of an effective treatment is needed in the future. This review provides an overview of heart failure in diabetic patients for the clinical practice of clinicians.
format Online
Article
Text
id pubmed-8999085
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89990852022-04-12 Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus Nakamura, Kazufumi Miyoshi, Toru Yoshida, Masashi Akagi, Satoshi Saito, Yukihiro Ejiri, Kentaro Matsuo, Naoaki Ichikawa, Keishi Iwasaki, Keiichiro Naito, Takanori Namba, Yusuke Yoshida, Masatoki Sugiyama, Hiroki Ito, Hiroshi Int J Mol Sci Review There is a close relationship between diabetes mellitus and heart failure, and diabetes is an independent risk factor for heart failure. Diabetes and heart failure are linked by not only the complication of ischemic heart disease, but also by metabolic disorders such as glucose toxicity and lipotoxicity based on insulin resistance. Cardiac dysfunction in the absence of coronary artery disease, hypertension, and valvular disease is called diabetic cardiomyopathy. Diabetes-induced hyperglycemia and hyperinsulinemia lead to capillary damage, myocardial fibrosis, and myocardial hypertrophy with mitochondrial dysfunction. Lipotoxicity with extensive fat deposits or lipid droplets is observed on cardiomyocytes. Furthermore, increased oxidative stress and inflammation cause cardiac fibrosis and hypertrophy. Treatment with a sodium glucose cotransporter 2 (SGLT2) inhibitor is currently one of the most effective treatments for heart failure associated with diabetes. However, an effective treatment for lipotoxicity of the myocardium has not yet been established, and the establishment of an effective treatment is needed in the future. This review provides an overview of heart failure in diabetic patients for the clinical practice of clinicians. MDPI 2022-03-25 /pmc/articles/PMC8999085/ /pubmed/35408946 http://dx.doi.org/10.3390/ijms23073587 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nakamura, Kazufumi
Miyoshi, Toru
Yoshida, Masashi
Akagi, Satoshi
Saito, Yukihiro
Ejiri, Kentaro
Matsuo, Naoaki
Ichikawa, Keishi
Iwasaki, Keiichiro
Naito, Takanori
Namba, Yusuke
Yoshida, Masatoki
Sugiyama, Hiroki
Ito, Hiroshi
Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus
title Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus
title_full Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus
title_fullStr Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus
title_full_unstemmed Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus
title_short Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus
title_sort pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999085/
https://www.ncbi.nlm.nih.gov/pubmed/35408946
http://dx.doi.org/10.3390/ijms23073587
work_keys_str_mv AT nakamurakazufumi pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus
AT miyoshitoru pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus
AT yoshidamasashi pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus
AT akagisatoshi pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus
AT saitoyukihiro pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus
AT ejirikentaro pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus
AT matsuonaoaki pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus
AT ichikawakeishi pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus
AT iwasakikeiichiro pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus
AT naitotakanori pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus
AT nambayusuke pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus
AT yoshidamasatoki pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus
AT sugiyamahiroki pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus
AT itohiroshi pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus